CheckMyRecalls

Cipla USA, Inc. recalls

12 recall notices naming Cipla USA, Inc. since January 2025, in United States. The most recent was published 14 Oct 2026.

Latest recalls (12)

  1. Cipla USA, Inc. recalls Fosfomycin Tromethamine Granules for Oral SolutionFDAFailed Impurities/Degradation Specifications
  2. Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
  3. Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
  4. Cipla USA, Inc. recalls Lanreotide InjectionFDALack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
  5. Cipla USA, Inc. recalls Nilotinib CapsulesFDAFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual…
  6. Cipla USA, Inc. recalls Diclofenac Sodium Topical GelFDAFailed PH Specifications
  7. Cipla USA, Inc. recalls Lanreotide InjectionFDAPresence of Particulate Matter.
  8. Cipla USA, Inc. recalls Lanthanum Carbonate chewable tabletsFDAFailed stability specifications: Out of specification for hardness test
  9. Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsFDACGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
  10. Cipla Limited recalls Phytonadione Injectable EmulsionFDAFailed Stability Specifications: Observed OOS results: eg results for colour index
  11. Cipla USA, Inc. recalls Albuterol SulfateFDAFailed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at…
  12. Cipla USA, Inc. recalls Budesonide Inhalation SuspensionFDALack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.